title: Foster Kennedy Syndrome: An Atypical Presentation.
abstract: OBJECTIVE
  To describe an unusual presentation of Foster Kennedy syndrome (FKS; unilateral optic nerve atrophy with optic nerve edema in the other eye) with optic nerve atrophy and retinal vein occlusion. It is an example of how common clinical features can hide a rare condition or presentation of a disease. Foster Kennedy syndrome is uncommon. Therefore, a space-occupying lesion should be suspected when there is optic atrophy associated with acute pathology of the other eye.
  
  
  METHODS
  A 56-year-old man presented with hemiretinal retinal vein occlusion in his right eye. He had previous optic nerve atrophy in his left eye attributed to nonarteritic anterior ischemic optic neuropathy. He lacked cardiovascular or prothrombotic risk factors. Consideration was given whether the presence of contralateral optic atrophy was associated with the retinal vein occlusion. A computed tomographic scan revealed a suprasellar mass. The tumor was excised and identified as meningioma.
  
  
  CONCLUSIONS
  Although typical FKS would present with optic nerve atrophy and contralateral optic nerve edema secondary to an intracranial mass, in this case, edema was replaced by a hemiretinal vein occlusion. In optic atrophy that does not show characteristic visual field alterations, typical symptoms, or the classic evolution of a given disease, diagnostic imaging may reveal the etiology. As FKS is uncommon, when there is optic atrophy associated with acute pathology of the other eye, a space-occupying lesion should be suspected.
authors.affiliation: *MD †MD, PhD Ophthalmology Department, Complejo Hospitalario de Pontevedra, Pontevedra, Spain (AP-F, MS, FJC, EV); and School of Medicine, University of Santiago de Compostela, Spain (CC).
authors.forename: Alberto
authors.initials: A
authors.lastname: Parafita-Fernández
authors.forename: Marta
authors.initials: M
authors.lastname: Sampil
authors.forename: Carlos
authors.initials: C
authors.lastname: Cores
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Cores
authors.forename: Eloy
authors.initials: E
authors.lastname: Viso
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000175:diagnosis* / Q000601:surgery; D008579:Meningioma / Q000175:diagnosis* / Q000601:surgery; D008875:Middle Aged; D009896:Optic Atrophy / Q000175:diagnosis / Q000628:therapy; D009901:Optic Nerve Diseases / Q000175:diagnosis* / Q000628:therapy; D012170:Retinal Vein Occlusion / Q000175:diagnosis* / Q000628:therapy; D041623:Tomography, Optical Coherence; D014057:Tomography, X-Ray Computed; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014794:Visual Fields
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab